Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (4), 519-525
- https://doi.org/10.1016/j.jacc.2003.09.043
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed.Cleveland Clinic Journal of Medicine, 2001
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1999
- Nonsteroidal Antiinflammatory Drugs — Differences and SimilaritiesNew England Journal of Medicine, 1991
- Clinical pharmacology of platelet cyclooxygenase inhibition.Circulation, 1985
- Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosaNature, 1980